# Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

> **NCT04129528** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** CFZ533
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04129528
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-08
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-06-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129528, "Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04129528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*